DUBLIN, Nov. 12, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the third quarter of 2024 ...

Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm finds it “frustrating” that despite the favorable Zantac settlement, robust ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

GSK’s Trelegy, a treatment for chronic obstructive pulmonary disease (COPD), aimed to address a gap in the market with its ...

Cash and cash equivalents amounted to EUR 550.9 million at the end of September 2024, increasing from EUR 402.5 million at the end of 2023. The ...

The print ads featured a prominent display of a person’s back, highlighting where shingles rashes typically emerge.

ii This approval underscores GSK's commitment to help drive progress for people living with complex blood cancers.

In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...

GSK has licensed a small molecule for Parkinson's and is teaming up on additional targets for the disease and another ...

Artists behind the new designs said they drew inspiration from across East Tennessee, hoping to highlight locations and elements from throughout the area. Luis Lopez is the main artist and visionary ...